Plus Therapeutics (PSTV) Liabilities and Shareholders Equity (2016 - 2025)
Plus Therapeutics (PSTV) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $18.7 million as the latest value for Q3 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 167.56% to $18.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $47.7 million, a 35.54% increase, with the full-year FY2024 number at $6.6 million, down 41.75% from a year prior.
- Liabilities and Shareholders Equity was $18.7 million for Q3 2025 at Plus Therapeutics, up from $10.4 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $24.8 million in Q3 2021 to a low of $5.6 million in Q1 2024.
- A 5-year average of $15.7 million and a median of $14.9 million in 2023 define the central range for Liabilities and Shareholders Equity.
- Peak YoY movement for Liabilities and Shareholders Equity: crashed 64.06% in 2024, then soared 167.56% in 2025.
- Plus Therapeutics' Liabilities and Shareholders Equity stood at $24.8 million in 2021, then fell by 3.57% to $23.9 million in 2022, then tumbled by 52.29% to $11.4 million in 2023, then plummeted by 41.75% to $6.6 million in 2024, then skyrocketed by 181.47% to $18.7 million in 2025.
- Per Business Quant, the three most recent readings for PSTV's Liabilities and Shareholders Equity are $18.7 million (Q3 2025), $10.4 million (Q2 2025), and $12.1 million (Q1 2025).